price may
result recoveri sale growth
oper leverag
result allevi investor concern growth slow core
sleep busi view sleep busi achiev cc revenu growth vs
despit high comp number row devic compani
result also demonstr compani benefit fix cost oper lever-
age ebitda margin expans y/i maintain posit outlook
compani forecast ep compound-annual-growth-rate retain buy
recommend given high tsr impli forecast tp
report result line revenu gross profit
forecast exceed earn forecast report revenu vs
dbe gross profit vs dbe underli ebit vs
dbe underli npat vs dbe
increas america mask growth increas row devi-
ce growth assum slower growth rate increas
row mask growth lower tax rate within compa-
ny guidanc also updat fx assumpt led ep
reduct net impact chang ep forecast
valuat risk
revis tp deriv use dcf valuat methodolog
dcf use wacc coe d/ev downsid
risk includ advers chang reimburs new competitor product
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
increas america mask growth
increas row devic growth assum slower growth
rate
increas row mask growth
lower tax rate within compani guidanc
updat fx assumpt led ep reduct
net impact chang ep forecast
report result line revenu gross profit
forecast exceed earn forecast report revenu vs
dbe gross profit vs dbe underli ebit vs
dbe underli npat vs dbe
highlight result includ
cy group revenu growth excl saa nice improv
growth report growth support growth america
devic growth america mask accessori growth row
mask accessori appear return take market share
america segment america excl saa segment report revenu
y/i vs pcp dbe america devic reve-
nue growth y/i vs came
dbe america mask accessori revenu growth remain strong
vs dbe manage-
ment note new mask well recent launch mask
rest world segment row segment report revenu
y/i cc growth vs pcp came dbe growth rate row
devic cc revenu growth vs manage-
ment said franc japan devic sale low due fleet upgrad previ-
ou period howev partial off-set growth market manage-
ment expect franc japan devic sale remain low
row mask accessori cc growth y/i vs
dbe manag said upgrad tele-monitor devi-
ce help drive higher mask sale
figur rest world revenu growth
saa segment saa segment report revenu y/i vs
pcp line dbe manag said exist brightre
busi achiev mid-to-high singl digit revenu growth matrixcar
achiev low doubl digit revenu growth manag believ achiev
low doubl digit growth saa busi medium term sustain
level growth manag said propel health busi ep dilu-
tive quarter line previou guidanc howev discuss
number pharmaceut compani commercialis product
figur saa revenu growth
devic total global devic growth y/i forecast
well came
mask accessori growth total global mask accessori growth
forecast achiev
gross margin gross margin dbe
margin improv due manufactur efficien-
cie favor product mix higher margin contribut matrixcar
partial off-set declin averag sell price manag
guid margin consist margin
sg sg expens y/i cc basi
exclud acquisit slighti dbe sg per-
centag sale slightli lower dbe manage-
ment expect sg expens sale manag note
continu achiev oper leverag busi
 expens y/i cc basi exclud-
ing acquisit dbe percentag sale
dbe manag expect
expens sale
underli ebit underli ebit came vs dbe
pcp translat ebit margin vs dbe
pcp
net interest expens net interest expens came vs dbe
pcp manag guid net interest expens
sale may
tax tax slightli dbe impli tax
rate vs dbe manag guid tax rate
lower previou guidanc
net debt compani report net debt vs dbe
dec gear increas vs dbe
cash-flow compani report opcf vs dbe
pcp ebitda cash convers ratio nine month vs
dbe
capital-expenditure compani report capital-expenditure vs dbe
dividend board declar dividend vs dbe
pcp
vs vs margin margin margin interest expens expens rate growth c/share c/share may
valuat risk
target price vs prev base
dcf valuat use three-stag dcf model discount post-tax free cash
flow target price reduc due primarili lower earn forecast
wacc assum beta coe risk-fre rate
assum long-term govern bond rate standard market risk premium
target d/ev forecast explicit cash flow follow hori-
zon period cash flow growth fade long-term termin valu
growth rate set termin growth rate slight premium
nomin global estim reflect long term demand trend rmd
signific reduct product fund reimburs
new innov product releas competitor lead market share
elev price pressur increas competit
model may numbersaustralasiaaustraliahealth biotechnologyresmedreut nbloomberg usbuypric may week cap profileresm global leader develop manufactur distribut market medic devic cloud-bas softwar applic diagnos treat managerespiratori disord price performanceresmedal ordinari rebas jan trendsebitda marginebit profitibilitysal growth lh roe debt/equ lh net interest cover year summarydb ep ep metricsprice/sal db report yield yield statement usdm flow cash raised/ bought inc/ dec investing/financ cash cash work sheet usdm cash plant sharehold compani metricssal growth ep growth ratio margin margin debt/equ interest cover analysisebit margin asset turnov financi cost ratio tax effect roa post tax financi leverag roe growth nta/shar average report growth compani data deutsch bank estim may
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
